Results from real world evidence presented at the ESC Congress 2018 advances clinical practice

This year, we will be showcasing data from real-world studies to advance understanding across cardio-renal-metabolic (CaReMe) diseases at the European Society of Cardiology (ESC) Congress in Munich, Germany, 25–29 August 2018. With 19 abstracts to be presented, we will advance our scientific leadership and continue to explore the overlap between cardiovascular, renal and metabolic diseases.

New pre-clinical and clinical data will be presented that aims to support optimum clinical practice in diverse patient populations who are at risk of, or have experienced cardiovascular events, and in patients with heart failure.

We have been a driving force in cardiovascular (CV) science for more than 100 years, and our presence at the ESC Congress will highlight our commitment to addressing cardiovascular diseases (CVD) as the number one cause of death globally1. Our focus is also to draw attention to the overlap between cardiovascular, renal, and metabolic diseases and their associated complications, and reflect this overlap in care of patients with these diseases.  

With this challenge in mind, we have adopted what we believe is a unique approach to Cardiovascular, Renal and Metabolism (CVRM). We have a clear strategy built around delivering life-changing results in the core CVD areas and their related complications and we are looking to do more than just slow CV-related diseases – we want to modify or even halt the natural course of the disease itself and help regenerate organs.

To take this pioneering step forward, we are not only investing in rigorous clinical trial programmes, but are also relying on strategic partners and world-leading experts, who are unafraid to take on the challenge of advancing science in CVRM.

During our conversations, presentations and presence at the ESC Congress we hope to embolden individuals and institutions working in this area to embrace our approach, while instilling confidence in our commitment to delivering next-generation science.  

Follow us on Twitter and LinkedIn, and join the conversation using #ESCCongress.

AstraZeneca is committed to addressing long term risk in cardiovascular disease


1.       World Health Organization. Cardiovascular diseases (CVDs): Key facts; 2017 [cited 2018 Jul 25]. Available from: URL:



Veeva ID: Z4-12157

Date of next review: August 2020